Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk

Cancer Detect Prev. 2005;29(2):124-32. doi: 10.1016/j.cdp.2004.11.002.

Abstract

Risk of epithelial ovarian cancer (EOC) attendant to use of hormone replacement therapy (HRT) was evaluated in a population-based case-control study of newly diagnosed EOC cases (n=256) and randomly selected population controls (n=1122). Telephone interviews were conducted to obtain information on history of HRT and several other covariates. Multivariate adjusted odds ratio (OR) and 95% confidence intervals (CI) were derived from unconditional logistic regression. The OR for ever use of HRT was 1.39 (95% CI: 1.01-1.93) compared to never use. Long-term use (>10 years) increased risk (OR: 1.62, CI: 1.05-2.50) although the trend p-value for duration of use was of only borderline significance (p=0.08). The relationship was stronger in women without hysterectomy (OR: 1.66, 95% CI: 1.14-2.41) or tubal ligation (OR: 1.56, 95% CI: 1.08-2.26). In this study, use of HRT is associated with an increased risk of EOC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Case-Control Studies
  • Epidemiologic Studies
  • Female
  • Hormone Replacement Therapy / adverse effects*
  • Humans
  • Hysterectomy
  • Middle Aged
  • Odds Ratio
  • Ovarian Neoplasms / etiology*
  • Risk Factors